Products Categories
| CAS No.: | 9039-53-6 |
|---|---|
| Name: | Urokinase |
| Molecular Structure: | |
|
|
|
| Formula: | Unspecified |
| Molecular Weight: | 0 |
| Synonyms: | Abbokinase;Actosolv;Breokinase;Double-chainurokinase-type plasminogen activator;E.C. 3.4.21.31;E.C. 3.4.21.73;E.C.3.4.99.26;Persolv;Plasminokinase, urinary;Pro-HGF convertase;Pro-hepatocytegrowth factor convertase;Purochin;Two-chain urokinase;Two-chainurokinase-type plasminogen activator;Ukidan;Urokinase;Urokinase plasminogenactivator;Urokinase-like plasminogen activator;Urokinase-type plasminogenactivator;Uronase;Win 22005;Win-Kinase; |
| EINECS: | 232-917-9 |
| Solubility: | Reconstitute in water at 100µg/ml |
| Hazard Symbols: | B |
| PSA: | 0.00000 |
| LogP: | 0.00000 |
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 97730-31-9(S)-4'-(2-Methylbutyl)Biphenyl-4-Carbonitrile
- 926293-55-26-Bromo-2-methylpyridine-3-carboxaldehyde
- 911112-05-55-Iodo-3-(trifluoromethyl)-2-pyridinamine
- 95789-13-21,3,7-trimethylpurine-2,6-dione
- 956104-42-02-Bromo-5-nitro-3-(trifluoromethyl)pyridine
- 910247-97-11,2,3-Trimethylimidazolium dimethyl phosphate
- 945683-37-41-butyl-2,3-dimethylimidazolium octanesulfate
What can I do for you?
Get Best Price
Consensus Reports
Reported in EPA TSCA Inventory.
Specification
The systematic name of Urokinase is Kinase (enzyme-activating), uro-. With the CAS registry number 9039-53-6, it is also named as Abbokinase. The product's classification codes are Drug / Therapeutic Agent; Plasminogen activator; Plasminogen Activators; Reproductive Effect; TSCA Flag XU [Exempt from reporting under the Inventory Update Rule], and the other registry numbers are 139639-24-0; 37211-64-6. Besides, it is white powder, which should be sealed in brown glass bottle at 2-8 °C. This chemical is a serine protease. In addition, The most important inhibitors of this chemical are the serpins plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2).
Preparation and Uses of Urokinase: this chemical was originally isolated from human urine. Additionally, this product can be used as anticancer agents. Moreover, it has been used clinically in the treatment of severe or massive deep venous thrombosis, pulmonary embolism, myocardial infarction, and occluded intravenous or dialysis cannulas as a thrombolytic agent.
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD50 | intravenous | > 909ug/kg (0.909mg/kg) | Drugs in Japan Vol. -, Pg. 164, 1990. | |
| mouse | LD50 | intravenous | > 3000ku/kg (3000000iu/kg) | Kiso to Rinsho. Clinical Report. Vol. 15, Pg. 514, 1981. | |
| mouse | LD50 | oral | > 2727ug/kg (2.727mg/kg) | Drugs in Japan Vol. -, Pg. 164, 1990. | |
| mouse | LD50 | subcutaneous | > 2727ug/kg (2.727mg/kg) | Drugs in Japan Vol. -, Pg. 164, 1990. | |
| rat | LD50 | intravenous | > 3000ku/kg (3000000iu/kg) | Kiso to Rinsho. Clinical Report. Vol. 15, Pg. 514, 1981. | |
| rat | LD50 | oral | > 2727ug/kg (2.727mg/kg) | Drugs in Japan Vol. -, Pg. 164, 1990. | |
| rat | LD50 | subcutaneous | > 2727ug/kg (2.727mg/kg) | Drugs in Japan Vol. -, Pg. 164, 1990. |